TSPyV Was Absent Across 25 Inflammatory Skin Biopsies
A California pathology series found no evidence of trichodysplasia spinulosa polyomavirus in endothelial cells across 25 inflammatory skin biopsy specimens, a result that pushes back against the idea that this virus commonly accompanies cutaneous inflammation. Investigators used RNAscope in situ hybridization on a mixed dermatopathology cohort that included vasculitic, interface, panniculitic, and nonspecific inflammatory patterns, along with one trichodysplasia spinulosa case as a positive control.
The negative result was not ambiguous. Endothelial staining was absent in every inflammatory specimen, while the positive control stained as expected and the RNA integrity probe was present in all samples. In practical terms, the assay worked, the tissue quality held up, and the survey still found no signal for TSPyV in this setting.
Why the Endothelial Signal Mattered in the First Place
Interest in this virus expanded after TSPyV was detected in endothelial cells from tumors in three separate patients, a finding that emerged through off-target next-generation sequencing reads and was later confirmed by in situ hybridization. That earlier observation raised an obvious question for dermatopathology: if the virus can reside in endothelial cells in tumors, could it also appear in vascular or inflammatory skin disease where endothelial activation and immune injury are already part of the pathology?
The biological appeal of that hypothesis is straightforward. Viruses that establish latent or tissue-specific infection can surface under immunosuppressive pressure, and endothelial cells are not passive bystanders in inflammation. They regulate leukocyte trafficking, vascular permeability, and local cytokine signaling, so a viral presence there could, at least in theory, intersect with vasculitic injury or steroid-associated immune shifts. These biopsies did not support that pathway.
The Cohort Spanned Vasculitis, Interface Dermatitis, and Panniculitis Patterns
The 25 specimens reflected a broad set of inflammatory diagnoses rather than a single disease entity. The cohort included leukocytoclastic vasculitis in 5 cases, medium-vessel vasculitis in 1, interface dermatitis in 6, perniosis in 2, tumid lupus in 1, erythema nodosum in 4, calciphylaxis in 1, and nonspecific epidermal dermatoses in 5. One trichodysplasia spinulosa sample served as the positive control.
Thirteen patients had received corticosteroids before biopsy. Ten of those were treated within 10 days of tissue sampling, while three had much longer intervals between steroid exposure and biopsy at 108 days, 1,494 days, and 1,949 days. Those intervals matter because corticosteroids have long been the clinical detail that draws attention in TSPyV-related work; the earlier endothelial tumor cases all involved corticosteroid exposure immediately before resection. Even with that clinical overlap present in this cohort, no endothelial infection was detected.
The absence of viral signal across multiple inflammatory phenotypes argues against a common relationship between TSPyV and routine inflammatory dermatoses. It also suggests that prior detection in endothelial tumor tissue should not be generalized to skin biopsies with vasculitic or interface-pattern inflammation. The clinical yield of searching for TSPyV in these specimens appears low.
Negative Tissue Findings Still Refine the Differential
A negative molecular pathology study can be useful when it narrows the tissue and disease contexts in which a pathogen deserves attention. Here, the result does not exclude TSPyV biology altogether; it simply confines the current evidence. Endothelial infection by this virus remains uncommon enough that a 25-case series did not capture it, and the earlier report that first identified TSPyV in endothelial cells involved 3 positive cases among 252 specimens.
That contrast is important. A rare signal can disappear quickly in a smaller cohort, especially when the positive state is sparse or tied to a very specific clinical setting. The data therefore fit two plausible interpretations: endothelial TSPyV may be genuinely uncommon in inflammatory skin disease, or the virus may occur at a frequency too low for a modest survey to detect. Either way, the practical message for dermatopathology is the same—routine inflammatory biopsy specimens are not a rich source of TSPyV positivity.
What the Assay Shows About Tissue-Based Virology
This study also reinforces the value of RNA in situ hybridization when the question is not just whether a viral sequence exists, but where it resides in tissue. The custom RNAscope probe targeted the complete TSPyV genome, while peptidylprolyl isomerase B served as a control for RNA integrity. That combination strengthens confidence in a true negative result because it separates absence of target signal from assay failure.
For pathologists, localization remains the critical issue. Viral DNA or RNA in a specimen can reflect contamination, latent carriage, bystander presence, or active tissue infection; localization within endothelial cells provides a more specific biological statement. Here, that statement could not be made for the inflammatory specimens. The only confirmed signal came from the trichodysplasia spinulosa control tissue.
The Clinical Boundaries Are Narrower After This Survey
The study’s main contribution is not a dramatic new association but a careful restriction of where TSPyV should be considered. Inflammatory skin biopsies, even those with vascular injury patterns and prior corticosteroid exposure, did not show endothelial infection in this series. For clinicians and pathologists, that means the virus should not be assumed to explain vasculitic or panniculitic inflammation on the basis of tissue tropism alone.
A larger cohort would be needed to define how rare the signal truly is. Until then, this series provides a clear, tissue-based negative finding: in these 25 California cases, TSPyV was not detected in endothelial cells, and the inflammatory diagnoses remained virologically unlinked to the virus under study.